PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

Articles

Search & filter insights:

Search & filter insights:

Evolve joins the ranks of the Legal 500

  • 1st November 2024
We are delighted to announce that Evolve has joined the ranks of the Legal 500 Intellectual Property firms. The Legal 500 is one of the UK’s leading legal directories, known for its rigorous research methodology and independent analysis of the legal market. As a small boutique IP firm, we are particularly proud of this achievement. …

Fishy evidence: Do we have the right sufficiency standard for therapeutic use? (T 1057/22)

  • 23rd September 2024
T 1057/22 related to a patent for the use of a rather unappetizing sounding fish oil and juice emulsion (“fish juice”) to treat cancer.

New USPTO Guidance on the use of AI in precision medicine

  • 17th September 2024
The USPTO recently issued Guidance on the patentability of AI. In the US, claims directed solely to a “judicial exception”, in the form of an abstract idea, natural phenomena, or law of nature, are not eligible for patent protection (35 U.S.C. 101). However, the case law on subject matter eligibility is infamously difficult to apply.…

UPC takes strong stance on therapeutic antibody inventions (Sanofi v Amgen, UPC_CFI_1/2023)

  • 12th August 2024
In its first-ever revocation order, the Unified Patent Court has deepened the transatlantic divide on biotech patents, confirming that what is patentable in the US may be considered obvious in Europe.

“Using AI tools to help assess inventive step”: A response to the CIPA journal article

  • 16th July 2024
This post is based on a previous article on IPKat. The cover article of the May 2024 edition of the CIPA Journal proposed a new test for inventive step using AI. The article was inspired by the EPO’s AI assisted search tool, AI-PreSearch. The CIPA journal article proposes to use an AI derived measurement of semantic similarity between the…

When is the inventor of an AI model also an inventor of the model’s output? A closer look at the USPTO Guidance for AI-Assisted Inventions

  • 16th July 2024
According to the USPTO guidance for AI-assisted inventions, AI has the potential to solve some of society’s most difficult challenges. However, in the patent realm, the USPTO also believes that “inventorship analysis should focus on human contributions, as patents function to incentivize and reward human ingenuity”. How then are AI-generated inventions to be protected?…

USPTO call for comments: Impact of AI on patentability

  • 16th June 2024
The USPTO has issued a request for comments regarding the impact of AI on patentability. The USPTO specifically calls for views on how the proliferation of AI could affect evaluations of patentability, including what qualifies as prior art and the capabilities of the person skilled in the art.

Inventive step of treating a subpopulation of patients in view of prior art reporting a positive phase 3 clinical trial (T 1437/21)

  • 30th April 2024
The European patent at issue in T 1437/21 (EP 2981271) related to the second medical use of a known drug (empagliflozin) in a subpopulation of patients.

First substantive decision of the UPC Court of Appeal overturns preliminary injunction in NanoString v 10x Genomics (UPC_CoA_335/2023)

  • 19th April 2024
In its first ever substantive decision, the UPC Court of Appeal (CoA) in Luxembourg has reversed the preliminary injunction ordered against NanoString by the Munich Local Division in 10x Genomics v NanoString. 

G 2/21: Is the technical effect embodied by the invention as originally disclosed?

  • 19th April 2024
The Enlarged Board of Appeal (EBA) has released its written decision in G 2/21 on the question of post-published evidence. In G 2/21, the EBA consciously avoids the rabbit hole of plausibility, dismissing it as a generic catch word that does not amount to a distinctive legal concept.

Gold Standard test for novelty reigns supreme, even for subranges (T 1688/20)

  • 8th February 2024
The EPO confirms that the selection of a subrange within a known broader range, is a patentable invention.

Don’t shoot yourself in the foot: European file history in US patent claim interpretation (K-fee v Nespresso)

  • 1st February 2024
This post is based on a previous article on IPKat. In the US, the principle of file wrapper estoppel is well established. Submissions made in US patent prosecution may be highly influential for claim interpretation post-grant. Additionally, as recently highlighted in K-fee v Nespresso (Case No. 22-2042, Fed. Cir. Dec. 26, 2023), file wrapper estoppel in the US does not…
Previous Next

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

Subscribe

Contact Us